43 related articles for article (PubMed ID: 10800167)
1. Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion.
Tamura T; Sasaki Y; Eguchi K; Shinkai T; Ohe Y; Nishio M; Kunikane H; Arioka H; Karato A; Omatsu H
Jpn J Cancer Res; 1994 Oct; 85(10):1057-62. PubMed ID: 7961108
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of 'high-dose' celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.
Abdel-Bary N; Hashem T; Metwali H; Abd El Ghany A; Magied H; El-Herbeiny M
Ecancermedicalscience; 2009; 3():144. PubMed ID: 22276009
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel.
Sousa-Pimenta M; Estevinho LM; Szopa A; Basit M; Khan K; Armaghan M; Ibrayeva M; Sönmez Gürer E; Calina D; Hano C; Sharifi-Rad J
Front Pharmacol; 2023; 14():1157306. PubMed ID: 37229270
[TBL] [Abstract][Full Text] [Related]
4. Primary breast lymphoma initially diagnosed as invasive ductal carcinoma: A case report.
Uenaka N; Yamamoto S; Sato S; Kudo T; Adachi S; Narui K; Tanabe M; Yamada A; Ishikawa T; Endo I
Clin Case Rep; 2021 Jun; 9(6):e04189. PubMed ID: 34194774
[TBL] [Abstract][Full Text] [Related]
5. Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.
Bowen RC; Hahn AW; Butler TW; Khong HT
Mol Clin Oncol; 2017 Jan; 6(1):122-124. PubMed ID: 28123744
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas.
Churpek JE; Pro B; van Besien K; Kline J; Conner K; Wade JL; Hagemeister F; Karrison T; Smith SM
Cancer; 2013 May; 119(9):1683-9. PubMed ID: 23310949
[TBL] [Abstract][Full Text] [Related]
7. Role of conventional salvage multiple-drug chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphomas.
Gobbi PG; Villano L; Pozzoli D; Bergonzi M
Oncol Lett; 2010 Jul; 1(4):679-683. PubMed ID: 22966363
[TBL] [Abstract][Full Text] [Related]
8. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-based treatment of lymphoma.
Younes A
Semin Oncol; 1999 Feb; 26(1 Suppl 2):123-8. PubMed ID: 10190794
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
13. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
Rizzieri DA; Sand GJ; McGaughey D; Moore JO; DeCastro C; Chao NJ; Vredenburgh JJ; Gasparetto C; Long GD; Anderson E; Foster T; Toaso B; Adams D; Niedzwiecki D; Gockerman JP
Cancer; 2004 Jun; 100(11):2408-14. PubMed ID: 15160345
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
